Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology & Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FASLG drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FASLG ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View FASLG Products |
| Gene Delivery | FASLG Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Membrane-bound native conformation. |
View FASLG Products |
| Receptor | FAS (CD95) ECD-Fc Protein Validated binding partner for competitive assays. |
View FAS Products |
| Benchmark Ab | Anti-FASLG Neutralizing Antibody Recombinant positive control for binding/blocking assays. |
View FASLG Products |
| Validator | FASLG siRNA Set For knockdown verification and specificity checks. |
View FASLG Products |
| Related Target A | FAS (CD95, TNFRSF6) Receptor-ligand pair; essential for apoptosis signal validation. |
View FAS Products |
| Related Target B | TNFSF10 (TRAIL) Parallel TNF superfamily apoptosis ligand; critical for selectivity profiling. |
View TNFSF10 Products |
| Related Target C | TNF (TNF-alpha) Comparative TNF superfamily member for specificity panels. |
View TNF Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Trimeric Conformation & Oligomerization | HEK293-expressed ECD-Fc; oligomerization-competent format verified by SEC; theoretical MW consistent with trimeric assembly. |
| Cross-species Cyno / Mouse / Human Evaluation | Human, Mouse, and Cynomolgus FASLG ortholog proteins available with >95% purity and sequence verified. |
| TNF Superfamily Selectivity (vs TNF, TRAIL, FAS) | Homolog panel proteins (FAS, TNFR1, TNFR2, DR4, DR5) strictly verified by mass spec; available for off-target binding assays. |
| Cell Surface vs Soluble Form Discrimination | Full-length lentivirus particles for membrane-presented native conformation; Soluble ECD for biochemical assays. |
| Lack of Validated Positive Controls | Clinical Benchmark Antibodies (Research Grade) and fusion protein biosimilars included as positive controls for neutralization assays. |
| False Positives / Specificity Checks | Validated siRNA included for target-specificity verification in cell-based assays. |
Live FASLG/CD178 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FASLG-targeted therapeutics has evolved significantly. Early attempts at systemic agonizing of the Fas/FasL pathway met severe roadblocks due to lethal hepatotoxicity, leading to a strategic pivot. Today, the field bifurcates: antagonistic biologics (decoy receptors and blocking antibodies) advance for autoimmune and inflammatory indications, while engineered FASLG trimers, bispecifics, and conditionally active agonists are explored in oncology to reactivate Fas-mediated apoptosis within the tumor microenvironment. As first-generation decoy receptor fusion proteins (e.g., CD95-Fc) progress through clinical stages, the next wave of R&D focuses on spatial control, avidity modulation, trimer-stabilized variants, ADCs targeting FASLG-expressing immune cells, and combinatorial regimens with immune checkpoint inhibitors. Autoimmune indications (Multiple Sclerosis, Graft-vs-Host Disease) dominate the agonist pipeline, whereas oncology prioritizes antagonists to block tumor immune evasion.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Decoy Receptor (CD95-Fc) | Apogenix (Asunercept), Genentech | Glioblastoma, Ophthalmic inflammation, MDS | Ligand Blocking Assay (Need high-purity, trimeric FASLG ECD) |
| Antagonistic mAb | Merck, BMS, Early-stage immunology cos | Autoimmune hepatitis, SLE, Solid tumors | Neutralization Assay (Need human and cyno FASLG cross-reactivity) |
| Agonist Trimer Engineering | ApoXis, Various Biotech | Solid tumors | Apoptosis Induction Assay (Need native trimeric ECD-Fc and FAS receptor panel) |
| Targeted Multimeric Agonist | Preclinical groups | Solid tumors | Trimerization Validation (Need intact, sequence-verified ECDs) |
| Bispecific T-cell Engager | Preclinical innovators | Refractory cancers | Cell-based Cytotoxicity Assay (Need Lentivirus for target cells) |
| Small Molecule / Peptide Modulator | Academic spin-offs, Early phase | Autoimmune, GVHD, Inflammatory diseases | Selectivity Assay (Need High-Purity Ortholog Proteins, mutant vs WT) |
| ADC | Emerging biotech | Autoimmune (targeted cell depletion) | Internalization Assay (Need conformation-stable ECD) |